A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements

FAN Editor

This article was originally published on ETFTrends.com.

A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug candidate and its expansion into other novel CRISPR developments. The ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG), which provides exposure to CRISPR, gene editing, therapeutics, agricultural biology and […]

Continue Reading Below

Read more at ETFTrends.com >

Free America Network Articles

Leave a Reply

Next Post

Form 1040? Simple. Its 6 new schedules? Harder

The new Form 1040 that all tax filers will file this year is a one-page document with just 23 lines. It replaces the old 1040 as well as the Form 1040A and Form 1040EZ, and for most tax filers with simple situations — income from one job, no children, one […]